Eliška Potůčková

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorková, Markéta Žaliová, Nicola C. Venn et al. · Blood · 2017 · 134 citations · Full text

Life Sciences, Genetics, Pediatrics +7

Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships

Maciej Serda, Danuta S. Kalinowski, Nathalie B. Rasko et al. · PLoS ONE · 2014 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications

Kateřina Hrušková, Eliška Potůčková, Tereza Hergeselová et al. · European Journal of Medicinal Chemistry · 2016 · 47 citations

Medicine, Chemistry, Pharmacology +14

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents

Vít Šesták, Ján Stariat, Jolana Cermanová et al. · Oncotarget · 2015 · 45 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

<i>ERG</i> deletions in childhood acute lymphoblastic leukemia with <i>DUX4</i> rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity

Markéta Žaliová, Eliška Potůčková, Lenka Hovorková et al. · Haematologica · 2019 · 44 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15